Navigation Links
United Therapeutics Corporation Announces Stock Split To Be Effected as a Stock Dividend
Date:9/1/2009

SILVER SPRING, Md., Sept. 1 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that its Board of Directors has approved and declared a stock split. The stock split will be effected in the form of a stock dividend, in which one share of United Therapeutics common stock will be distributed for each share of common stock issued and outstanding (or held in treasury) at the close of business on the record date, September 14, 2009. The additional shares of common stock are scheduled to be distributed on September 22, 2009, to all shareholders of record by BNY Mellon, United Therapeutics' transfer agent. United Therapeutics expects that its common stock will begin to trade on the NASDAQ Global Select Market on a split-adjusted basis beginning on September 23, 2009.

"Just as the recent approval of our new medicine, Tyvaso, has provided doctors and patients with a 2-for-1 therapeutic opportunity, by having both inhaled and parenteral forms of treprostinil to prescribe, today's announcement provides shareholders with a 2-for-1 investment opportunity, by doubling the number of outstanding shares from approximately 27 million to 54 million," said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "Even with this split, our number of outstanding shares is still well below that of other similar stage biotechnology companies."

About United Therapeutics

United Therapeutics is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer.

Forward-looking Statements

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, the future timing and benefits of the stock split and the opportunities created by the launch of Tyvaso. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and current reports on Form 8K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of September 1, 2009, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason. [uthr-g]

Tyvaso is a trademark of United Therapeutics Corporation.


'/>"/>
SOURCE United Therapeutics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for Pulmonary Arterial Hypertension in the United States
2. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
3. Wyeth Provides Regulatory Update on Prevnar 13* in the United States
4. Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
5. United States FDA Clears the REGEN Trial to Test Biohearts Combination Gene and Stem Cell Therapy in Heart Failure Patients
6. United Therapeutics Corporation to Announce Second Quarter 2009 Financial Results Before Market Open on Friday, July 31, 2009
7. LS9's UltraClean Diesel Exceeds United States & Brazilian Fuels Specifications
8. NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State
9. Americans United for Life: Obamas Disbanding Bioethics Council Raises Troubling Questions
10. MedMira Strengthens North American Sales Channels, Adding VWR as Distributor for the United States
11. The Chiesi Group Lands in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... Philadelphia, PA (PRWEB) , ... October 10, 2017 ... ... University City Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. ... accept the award for Excellence in Volunteer Experience from US2020. , US2020’s mission ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... innovation and business process optimization firm for the life sciences and healthcare industries, ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board meeting in North ... in Harvard University’s Departments of Physics and Astronomy, has been selected for membership in ... winning team for the 2015 Breakthrough Prize in Fundamental physics for the discovery of ...
(Date:10/7/2017)... ... October 06, 2017 , ... Phase ... metagenome deconvolution product, featuring the first commercially available Hi-C kit. Researchers can ... Hi-C metagenome deconvolution using their own facilities, supplementing the company’s full-service ProxiMeta ...
Breaking Biology Technology:
(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:4/11/2017)... -- NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" ... of independent Directors Mr. Robin D. Richards and ... furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer ... guidance and benefiting from their considerable expertise as we move ...
(Date:4/5/2017)...  The Allen Institute for Cell Science today announces ... portal and dynamic digital window into the human cell. ... application of deep learning to create predictive models of ... a growing suite of powerful tools. The Allen Cell ... publicly available resources created and shared by the Allen ...
Breaking Biology News(10 mins):